Why Novo Nordisk Is Putting $2 Billion Into a Pill

Novo Nordisk and Vivtex join forces in a $2.1B deal to develop next-generation oral biologics for obesity and diabetes

17 Mar 2026

Medical history is often a struggle against the chemistry of the human stomach. For years, the most effective treatments for diabetes and obesity have been biologics, which are large, fragile molecules that gastric acid tends to tear apart. Patients have had little choice but to endure the frequent sting of a needle to ensure these drugs reach the bloodstream intact. Now, Novo Nordisk, a Danish firm that has grown remarkably wealthy on the back of injectable weight-loss treatments, wants to make the syringe obsolete.

A new partnership with Vivtex, a biotech firm born out of MIT, aims to solve this "delivery problem." The deal, announced in February 2026 and valued at up to $2.1 billion, focuses on shielding biologics as they travel through the digestive tract. While Novo already sells an oral version of its blockbuster drug, semaglutide, the physics of absorption remains inefficient. Much of the pill is wasted; only a tiny fraction of the active ingredient actually does its job.

Simplicity is the primary driver here. Patients generally prefer swallowing a tablet to injecting themselves, and for Novo Nordisk, shifting the market toward pills is a defensive necessity. Competition is intensifying as rivals race to launch their own versions of these "miracle" drugs. By securing the screening platform developed by Vivtex and its co-founder, the prolific scientist Robert Langer, Novo hopes to find formulations that are both cheaper to produce and easier to distribute.

Financial stakes are high, with Vivtex eligible for research funding and milestone payments while Novo Nordisk handles the heavy lifting of manufacturing and global sales. If successful, the partnership could turn a specialized medical treatment into a routine daily habit for millions.

Moving from the clinic to the pharmacy shelf is rarely a straight line, however. Science has long promised oral biologics, only for many candidates to fail in late-stage trials due to unpredictable absorption rates. For now, the Danish giant is betting that $2 billion is a fair price to pay for the chance to turn a medical breakthrough into a household commodity.